BR9914051A - Métodos para administração de antibióticos - Google Patents

Métodos para administração de antibióticos

Info

Publication number
BR9914051A
BR9914051A BR9914051-9A BR9914051A BR9914051A BR 9914051 A BR9914051 A BR 9914051A BR 9914051 A BR9914051 A BR 9914051A BR 9914051 A BR9914051 A BR 9914051A
Authority
BR
Brazil
Prior art keywords
administering
daptomycin
methods
muscle toxicity
skeletal muscle
Prior art date
Application number
BR9914051-9A
Other languages
English (en)
Inventor
Frederick B Oleson Jr
Francis P Tally
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9914051(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of BR9914051A publication Critical patent/BR9914051A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção: <B>"MéTODOS PARA ADMINISTRAçãO DE ANTIBIóTICOS"<D>. A presente invenção refere-se a métodos para administrar uma quantidade eficaz terapeuticamente de daptomicina enquanto minimizando toxicidade do músculo esquelético. Os métodos fornecem administração de daptomicina em um intervalo de dosagem de 24 horas ou maior. Este intervalo de dosagem longo minimiza toxicidade do músculo esquelético e permite pico maior de concentração de daptomicina, o qual é relacionado a eficácia de daptomicina. A invenção também fornece métodos de administrar antibiótico de lipopeptídeos outros além de daptomicina enquanto minimizando toxicidade do músculo esquelético administrando uma quantidade eficaz terapeuticamente do antibiótico de lipopeptídeo em um intervalo de dosagem que não resulta em toxicidade muscular. A invenção também fornece métodos de administrar quinopristina/dalfopristina enquanto minimizando toxicidade do músculo esquelético administrando uma quantidade eficaz terapeuticamente de quinopristina/dalfopristina em um intervalo de dosagem que não resulta em toxicidade muscular.
BR9914051-9A 1998-09-25 1999-09-24 Métodos para administração de antibióticos BR9914051A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24
PCT/US1999/022366 WO2000018419A2 (en) 1998-09-25 1999-09-24 Methods for administration of antibiotics

Publications (1)

Publication Number Publication Date
BR9914051A true BR9914051A (pt) 2001-06-19

Family

ID=26798675

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914051-9A BR9914051A (pt) 1998-09-25 1999-09-24 Métodos para administração de antibióticos

Country Status (26)

Country Link
US (2) US6468967B1 (pt)
EP (2) EP1674107B8 (pt)
JP (4) JP4184607B2 (pt)
KR (2) KR20100051735A (pt)
CN (2) CN1530136A (pt)
AT (1) ATE322280T1 (pt)
AU (1) AU764348B2 (pt)
BR (1) BR9914051A (pt)
CA (1) CA2344318C (pt)
CY (3) CY1105556T1 (pt)
DE (3) DE122006000049I2 (pt)
DK (2) DK1115417T3 (pt)
ES (2) ES2603086T3 (pt)
HK (1) HK1040363B (pt)
HU (1) HU230656B1 (pt)
IS (2) IS5890A (pt)
LU (1) LU91254I2 (pt)
NL (1) NL300232I2 (pt)
NO (1) NO20011454L (pt)
NZ (1) NZ510690A (pt)
PL (2) PL203689B1 (pt)
PT (2) PT1674107T (pt)
RU (1) RU2363489C9 (pt)
SI (2) SI1674107T1 (pt)
TR (1) TR200100841T2 (pt)
WO (1) WO2000018419A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1530136A (zh) 1998-09-25 2004-09-22 ������ҩ�����޹�˾ 抗生素的给药方法
EP2298790A1 (en) 1999-12-15 2011-03-23 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
ATE535539T1 (de) * 2000-12-18 2011-12-15 Cubist Pharm Inc Verfahren zur herstellung gereinigter lipopeptide
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
AU2009222020A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
ES2763184T3 (es) 2008-07-17 2020-05-27 Acorda Therapeutics Inc Dosificación terapéutica de una neurregulina en el tratamiento o profilaxis de la insuficiencia cardíaca
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
BRPI0920026B1 (pt) 2008-10-07 2023-11-07 Horizon Orphan Llc Composição farmacêutica e respectivos usos
DK2346509T3 (da) 2008-10-07 2020-08-03 Horizon Orphan Llc Inhalation af levofloxacin til at reducere lungeinflammation
WO2010048630A1 (en) 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
MX2011006803A (es) * 2008-12-22 2011-09-06 Cubist Pharm Inc Agentes antibacterianos novedosos para el tratamiento de infecciones gram positivas.
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
IN2012DN02477A (pt) 2009-09-04 2015-08-21 Mpex Pharmaceuticals Inc
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
RU2014143821A (ru) 2012-03-30 2016-05-27 Кьюбист Фармасьютикалз, Инк. 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ
NZ706286A (en) * 2012-09-11 2018-05-25 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
CA2904387C (en) 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
CN1530136A (zh) 1998-09-25 2004-09-22 ������ҩ�����޹�˾ 抗生素的给药方法
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
PL206091B1 (pl) 2010-06-30
HUP0103874A3 (en) 2002-09-30
DE69930758T2 (de) 2007-04-26
EP1674107A3 (en) 2012-06-20
HK1040363A1 (en) 2002-06-07
ES2603086T3 (es) 2017-02-23
WO2000018419A2 (en) 2000-04-06
NL300232I1 (nl) 2006-09-01
NO20011454D0 (no) 2001-03-22
EP1674107B8 (en) 2017-01-25
DE122006000049I1 (de) 2007-01-04
DK1115417T3 (da) 2006-07-31
EP1674107A2 (en) 2006-06-28
AU764348B2 (en) 2003-08-14
KR20100051735A (ko) 2010-05-17
SI1674107T1 (sl) 2017-01-31
EP1674107A8 (en) 2006-10-04
NO20011454L (no) 2001-05-25
HUP0103874A2 (hu) 2002-02-28
RU2363489C2 (ru) 2009-08-10
CN1150029C (zh) 2004-05-19
HK1040363B (zh) 2007-01-26
RU2363489C9 (ru) 2010-03-20
DE69930758D1 (de) 2006-05-18
JP2004339238A (ja) 2004-12-02
CA2344318A1 (en) 2000-04-06
JP2003321389A (ja) 2003-11-11
ATE322280T1 (de) 2006-04-15
HU230656B1 (hu) 2017-06-28
ES2259845T3 (es) 2006-10-16
RU2004106569A (ru) 2005-08-10
PT1674107T (pt) 2016-12-07
DE122006000049I2 (de) 2007-11-08
DK1674107T3 (en) 2016-12-19
US20020142948A1 (en) 2002-10-03
US6852689B2 (en) 2005-02-08
IS5890A (is) 2001-03-14
JP2006335773A (ja) 2006-12-14
LU91254I2 (fr) 2006-08-28
PT1115417E (pt) 2006-07-31
SI1115417T1 (sl) 2006-08-31
AU6268799A (en) 2000-04-17
CA2344318C (en) 2006-07-04
CY2006003I1 (el) 2009-11-04
IS8807A (is) 2009-03-10
CN1530136A (zh) 2004-09-22
CY2006003I2 (el) 2009-11-04
EP1674107B1 (en) 2016-08-24
US6468967B1 (en) 2002-10-22
JP4184607B2 (ja) 2008-11-19
WO2000018419A3 (en) 2000-07-06
JP2002525335A (ja) 2002-08-13
NL300232I2 (nl) 2007-01-02
CY1105556T1 (el) 2010-07-28
EP1115417B1 (en) 2006-04-05
TR200100841T2 (tr) 2002-01-21
PL203689B1 (pl) 2009-11-30
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
KR20010075327A (ko) 2001-08-09
CN1348382A (zh) 2002-05-08
PL348328A1 (en) 2002-05-20
NZ510690A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
BR9914051A (pt) Métodos para administração de antibióticos
EA200000718A1 (ru) Композиции целекоксиба
DK0566709T5 (da) Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
PT705100E (pt) Guanidinas substituidas terapeuticas
RU2004110041A (ru) Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
AR029646A1 (es) Combinacion sinergistica que comprende cantidades efectivas de un antagonista de receptor de nk1 y un analogo de gaba, composiciones farmaceuticas de la misma y uso de dicha composicion
BR0012058A (pt) Combinação sinérgica: gabapentina e pregabalina
BR9812875A (pt) Processos para o tratamento de artrite reumatóide em um mamìfero, e para a fabricação de uma composição terapêutica para o tratamento de artrite reumatóide em um mamìfero, uso de um composto, e, composição farmacêutica
BR0204889A (pt) Kit para a redução de dor
BR0011884A (pt) Método de tratamento da obesidade e condições comórbidas em um ser humano necessitando de tal tratamento, composto da fórmula i, produto contendo o composto da fórmula i, uso do composto da fórmula i, e, composição farmacêutica
NO962503L (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
BR9911943A (pt) Composições compreendendo análogos gaba e um descongestionante para aliviar dor de cabeça de sino

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: CUBIST PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020100048642/RJ DE 31/05/2010.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII) E 11 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: CUBIST PHARMACEUTICALS, INC. (US)

B25H Request for change of headquarter rejected

Owner name: CUBIST PHARMACEUTICALS, INC. (US)